1. Touloukian CE, Leitner WW, Topalian SL, et al. Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol. 2000;164:3535–3542. [PMC free article] [PubMed] 2. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA. 1994;91:9461–9465. [PubMed] 3. Van der Bruggen P, Traversari C, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643–1647. [PubMed] 4. Houghton AN, Gold JS, Blachere NE. Immunity against cancer: lessons learned from melanoma. Curr Opin Immunol. 2001;13:134–140. [PubMed] 5. Parkinson DR, Abrams JS, Wiernik PH, et al. Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. J Clin Oncol. 1990;8:1650–1656. [PubMed] 6. Legha SS, Gianan MA, Plager C, et al. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer. 1996;77:89–96. [PubMed] 7. Sparano JA, Fisher RI, Sunderland M, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol. 1993;11:1969–1677. [PubMed] 8. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14:5610–5618. [PMC free article] [PubMed]
9. Agarwala SS, Tarhini AA, Kirkwood JM, et al. Phase II trial of sequential temozolomide (TMZ) and high-dose bolus (HDB) IL-2 in patients with metastatic melanoma. Journal of Clinical Oncology. 2006;24:18S–8037.
10. Sosman JA, Carrillo C, Urba WJ, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol. 2008;26:2292–2298. [PMC free article] [PubMed] 11. Kaufmann R, Spieth K, Leiter U, et al. Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol. 2005;23:9001–9007. [PubMed] 12. Bar J, Yerushalmi R, Shapira-Frummer R, et al. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma. Oncol Rep. 2008;20:1533–1538. [PubMed] 13. Hauschild A, Dummer R, Ugurel S, et al. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study. Cancer. 2008;113:1404–1411. [PubMed] 14. Spieth K, Kaufmann R, Dummer R, et al. Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG) Ann Oncol. 2008;19:801–806. [PubMed] 15. Alatrash G, Hutson TE, Molto L, et al. Clinical and immunologic effiects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol. 2004;22:2891–2900. [PubMed] 16. Senzer NN, Kaufman H, Amatruda T, et al. Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma. J Clin Oncol. 2009;27:5763–5771. [PubMed] 17. Rosenberg SA, Yang JC, Topalian SL. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA. 1994;271:907–913. [PubMed] 18. Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–897. [PubMed] 19. Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993;85:622–632. [PubMed] 20. Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(suppl 1):S11–S14. [PubMed] 21. Phan GQ, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol. 2001;19:3477–3482. [PubMed] 22. Sabatino M, Kim-Schulze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645–2652. [PMC free article] [PubMed]
23. Atkins MB, Shet A, Sosman JA. IL-2 clinical applications. In: De Vita VT Jr, Hellman S, Rosenberg SA, et al., editors. Biologic Therapy of Cancer Principles and Practice. 3rd ed Vol. 50. JB Lippincott; Philadelphia: 2000.
24. Maellaro E, Pacenti L, Del Bello B, et al. Diffierent effiects of interferon-alpha on melanoma cell lines: a study on telomerase reverse transcriptase, telomerase activity and apoptosis. Br J Dermatol. 2003;148:1115–1124. [PubMed] 25. Fleischmann CM, Stanton GJ, Fleischmann WR., Jr Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages. J Interferon Cytokine Res. 1996;16:805–812. [PubMed] 26. Streck CJ, Ng CY, Zhang Y, et al. Interferon-mediated anti-angiogenic therapy for neuroblastoma. Cancer Lett. 2005;228:163–170. [PubMed] 27. Sabel MS, Sondak VK. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma? Drugs. 2003;63:1053–1058. [PubMed]
28. Sondak VK, Redman BG. Chapter 16: Pharmacology of Cancer Biotherapeutics: Section 1: Interferons. In: De Vita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, Principals and Practice of Oncology. 7th ed JB Lippincot; Philadelphia: 2000.
29. Morton DL, Essner R, Kirkwood JM, et al. In: The Skin: Malignant Melanoma in Cancer Medicine. 6th ed Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. BC Decker; Hamilton, ON: 2003. pp. 1973–1997.
30. Astsaturov I, Petrella T, Bagriacik EU, et al. Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines. Clin Cancer Res. 2003;9:4347–4355. [PubMed] 31. Cangemi G, Morandi B, D'Agostino A, et al. IFN-alpha mediates the up-regulation of HLA class I on melanoma cells without switching proteasome to immunoproteasome. Int Immunol. 2003;15:1415–1421. [PubMed] 32. Marincola FM, White DE, Wise AP, et al. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol. 1995;13:1110–1122. [PubMed] 33. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997;3:409–417. [PubMed] 34. Bajetta E, Del Vecchio M, Mortarini R, et al. Pilot study of subcutaneous recombinant human interleukin 12 in meta-static melanoma. Clin Cancer Res. 1998;4:75–85. [PubMed] 35. Gollob JA, Veenstra KG, Parker RA, et al. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol. 2003;21:2564–2573. [PubMed] 36. Schiller JH, Pugh M, Kirkwood JM, et al. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design. Clin Cancer Res. 1996;2:29–36. [PubMed] 37. Atkins MB. Immunotherapy and experimental approaches for metastatic melanoma. Hematol Oncol Clin North Am. 1998;12:877–902. viii. [PubMed]
38. Robertson MJ, Mier J, Logan T, et al. Tolerability and anti-tumor activity of recombinant human IL-18 (rhIL-18) administered as five daily intravenous infusions in patients with solid tumors. Proc Am Soc Clin Oncology. 2004;22:14S. Abstr. 2553.
39. Ichim CV. Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. J Transl Med. 2005;3:8. [PMC free article] [PubMed] 40. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effiect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168–16173. [PubMed] 41. Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I–II dendritic cell-based immunotherapy of metastatic renal cancer. Int J Oncol. 2009;35:569–581. [PubMed] 42. Rosenberg SA, Yannelli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst. 1994;86:1159–1166. [PubMed] 43. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response. J Natl Cancer Inst. 1991;83:932–937. [PubMed] 44. Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol. 2004;173:7125–7130. [PMC free article] [PubMed] 45. Zhou J, Shen X, Huang J, et al. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J Immunol. 2005;175:7046–7052. [PMC free article] [PubMed] 46. Klebanoff CA, Khong HT, Antony PA, et al. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 2005;26:111–117. [PMC free article] [PubMed] 47. Marleau AM, Sarvetnick N. T cell homeostasis in tolerance and immunity. J Leukoc Biol. 2005;78:575–584. [PubMed] 48. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850–854. [PMC free article] [PubMed] 49. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346–2357. [PMC free article] [PubMed] 50. Van der Most RG, Currie AJ, Mahendran S, et al. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother. 2009;58:1219–1228. [PubMed] 51. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008;26:5233–5239. [PMC free article] [PubMed] 52. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21:233–240. [PMC free article] [PubMed] 53. Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–129. [PMC free article] [PubMed] 54. Heemskerk B, Liu K, Dudley ME, et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008;19:496–510. [PMC free article] [PubMed] 55. Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998;16:2921–2929. [PubMed]
56. Allen I, Kupelnick B, Kumashiro M. Efficacy of interleukin-2 in the treatment of metastatic melanoma-systematic review and meta-analysis. Sel Cancer Ther. 1998;1:168–173.
57. Alexandrescu DT, Dutcher JP, Wiernik PH. Metastatic melanoma: is biochemotherapy the future? Med Oncol. 2005;22:101–111. [PubMed] 58. Yannelli JR, Wroblewski JM. On the road to a tumor cell vaccine: 20 years of cellular immunotherapy. Vaccine. 2004;23:97–113. [PubMed] 59. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine. 2007;25(suppl 2):B4–B16. [PubMed] 60. Riley LB, Agarwala SS. Melanoma vaccines. Expert Rev Vaccines. 2008;7:937–949. [PubMed] 61. Rosenberg SA, White DE. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy. J Immunother Emphasis Tumor Immunol. 1996;19:81–84. [PubMed] 62. Wang E, Monaco A, Monsurro V, et al. Antitumor vaccines, immunotherapy and the immunological constant of rejection. IDrugs. 2009;12:297–301. [PMC free article] [PubMed] 63. Hersey P. Melanoma vaccines. Current status and future prospects. Drugs. 1994;47:373–382. [PubMed] 64. Vaishampayan U, Abrams J, Darrah D, et al. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res. 2002;8:3696–3701. [PubMed] 65. Mitchell MS, Abrams J, Thompson JA, et al. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol. 2007;25:2078–2085. [PubMed] 66. Pan J, Jin P, Yan J, et al. Anti-angiogenic active immunotherapy: a new approach to cancer treatment. Cancer Immunol Immunother. 2008;57:1105–1114. [PubMed] 67. Yuan J, Ku GY, Gallardo HF, et al. Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. Cancer Immun. 2009;9:5. [PMC free article] [PubMed] 68. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321–327. [PMC free article] [PubMed]
69. Ernstoff M, Carrillo C, Urba W, et al. A cytokine working group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide +high dose (HD) interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts) Proc Am Soc Clin Oncology. 2005;23:16S. Abstr. 7504.
70. Smith JW, II, Walker EB, Fox BA, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol. 2003;21:1562–1573. [PubMed] 71. Slingluff CL, Jr, Yamshchikov G, Neese P, et al. Phase I trial of a melanoma vaccine with gp100 (280–288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Cancer Res. 2001;7:3012–3024. [PubMed] 72. Cormier JN, Salgaller ML, Prevette T, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am. 1997;3:37–44. [PMC free article] [PubMed] 73. Bettinotti MP, Panelli MC, Ruppe E, et al. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170–178. Int J Cancer. 2003;105:210–216. [PubMed] 74. Roberts JD, Niedzwiecki D, Carson WE, et al. Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 2006;29:95–101. [PubMed] 75. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol. 1999;163:6292–6300. [PubMed]
76. Schwartzentruber D. A phase III multi-institutional randomized study of immunization with the gp100:209-217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J Clin Oncol. 2009;27(suppl):18s. abstr CRA9011.
77. Kirkwood JM, Lee S, Moschos SJ, et al. Immunogenicity and antitumor effects of vaccination with peptide vaccine± granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin Cancer Res. 2009;15:1443–1451. [PMC free article] [PubMed] 78. Gajewski TF, Fallarino F, Ashikari A, et al. Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12. Clin Cancer Res. 2001;7(3 suppl):895s–901s. [PubMed] 79. Cebon J, Jager E, Shackleton MJ, et al. Two phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 2003;3:7. [PubMed] 80. Schaed SG, Klimek VM, Panageas KS, et al. T-cell responses against tyrosinase 368–376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin Cancer Res. 2002;8:967–972. [PubMed] 81. Jager E, Gnjatic S, Nagata Y, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A. 2000;97:12198–12203. [PubMed] 82. Young MR, Wright MA, Lozano Y, et al. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer. 1997;74:69–74. [PubMed] 83. Young MR, Wright MA, Matthews JP, et al. Suppression of T cell proliferation by tumor-induced granulocyte-macro-phage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol. 1996;156:1916–1922. [PubMed] 84. Parmiani G, Castelli C, Pilla L, et al. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol. 2007;18:226–232. [PubMed] 85. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539–3543. [PubMed] 86. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998;95:13141–13146. [PubMed] 87. Nawrocki S, Murawa P, Malicki J, et al. Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett. 2000;74:81–86. [PubMed] 88. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol. 2005;78:1043–1051. [PubMed] 89. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998;90:1894–1900. [PMC free article] [PubMed] 90. Bergen M, Chen R, Gonzalez R. Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma. Expert Opin Biol Ther. 2003;3:377–384. [PubMed]
91. Richards JM, Bedikian A, Gonzalez R, et al. High-dose Allovectin-7® in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. Proc Am Soc Clin Oncology. 2005;23:16S. Abstr. 7543.
92. Ilkovitch D, Lopez DM. Immune modulation by melanoma-derived factors. Exp Dermatol. 2008;17:977–985. [PubMed] 93. Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity. Clin Exp Immunol. 2006;146:189–196. [PubMed] 94. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol. 2003;170:1304–1312. [PubMed] 95. Nicholaou T, Ebert LM, Davis ID, et al. Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma. Clin Cancer Res. 2009;15:2166–2173. [PubMed] 96. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332. [PubMed] 97. Banchereau J, Palucka AK, Dhodapkar M, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 2001;61:6451–6458. [PubMed] 98. Lau R, Wang F, Jeffery G, et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother. 2001;24:66–78. [PubMed] 99. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopre-served, peptide-loaded monocyte-derived dendritic cells. J Exp Med. 2002;195:1279–1288. [PMC free article] [PubMed] 100. Smithers M, O'Connell K, MacFadyen S, et al. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen. Cancer Immunol Immunother. 2003;52:41–52. [PubMed] 101. Slingluff CL, Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol. 2003;21:4016–4026. [PubMed] 102. O'Rourke MG, Johnson M, Lanagan C, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387–395. [PubMed] 103. Ribas A, Glaspy JA, Lee Y, et al. Role of dendritic cell phenotype, determinant spreading, and negative costimula-tory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004;27:354–367. [PubMed]
104. Gorin I, Prince M, Grob J, et al. A phase I/II study of a multivalent dendritic cell vaccine in patients with metastatic melanoma. Journal of Clinical Oncology. 2005;23:16S. ASCO Annual Meeting Proceedings. Part I of II, 2542.
105. Akiyama Y, Tanosaki R, Inoue N, et al. Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med. 2005;3:4. [PMC free article] [PubMed] 106. Palucka AK, Ueno H, Connolly J, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006;29:545–557. [PubMed] 107. Ridolfi R, Petrini M, Fiammenghi L, et al. Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med. 2006;4:36. [PMC free article] [PubMed] 108. Salcedo M, Bercovici N, Taylor R, et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother. 2006;55:819–829. [PubMed]
109. Ross M, Camacho LH, Hersh EM, et al. Clinical and Immunological responses in patients with malignant melanoma treated with a dendritic cell-based vaccine. Preliminary report from a multi-institutional phase II clinical trial. Journal of Clinical Oncology. 2007;25(18S (June 20 Supplement)):3004. 2007 ASCO Annual Meeting Proceedings. Part I.
110. O'Rourke MG, Johnson MK, Lanagan CM, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007;17:316–322. [PubMed]
111. Petenko NN, Mikhaylova I, Chkadua GZ, et al. Dendritic cell based vaccine therapy of melanoma. Journal of Clinical Oncology. 2007;25(18S (June 20 Supplement)):3077. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition)
112. Wei YC, Stephenson JJ, Li K, et al. A phase II clinical study of dendritoma vaccination combined with low dose inter-leukin-2 in advanced melanoma patients. Journal of Clinical Oncology. 2007;25(18S):3051. ASCO Annual Meeting Proceedings Part I.
113. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243–251. [PubMed] 114. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091–5100. [PubMed] 115. Dhodapkar MV, Krasovsky J, Steinman RM, et al. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest. 2000;105:R9–R14. [PMC free article] [PubMed] 116. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999;190:1669–1678. [PMC free article] [PubMed] 117. Banchereau J, Fay J, Pascual V, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Novartis Found Symp. 2003;252:226–235. discussion 35–8, 57–67. [PubMed] 118. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008;31:294–309. [PMC free article] [PubMed] 119. Engell-Noerregaard L, Hansen TH, Andersen MH, et al. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1–14. [PubMed] 120. Rosenberg SA, Sherry RM, Morton KE, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169–6176. [PubMed] 121. Tuettenberg A, Becker C, Huter E, et al. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int J Cancer. 2006;118:2617–2627. [PubMed] 122. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563–570. [PubMed] 123. Jackson AM, Mulcahy LA, Zhu XW, et al. Tumour-mediated disruption of dendritic cell function: inhibiting the MEK1/2-p44/42 axis restores IL-12 production and Th1-generation. Int J Cancer. 2008;123:623–632. [PubMed] 124. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20:4169–4180. [PubMed]
125. Parmiani G. Phase II study of HSPPC-96 in combination with GM-CSF and IFN-a in stage IV malignant melanoma. Proc Am Soc Clin Oncology. 2004
126. Testori A, Richards J, Whitman E, et al. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008;26:955–962. [PubMed] 127. Chang CC, Ogino T, Mullins DW, et al. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. J Biol Chem. 2006;281:18763–18773. [PubMed] 128. Chang CC, Campoli M, Restifo NP, et al. Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J Immunol. 2005;174:1462–1471. [PMC free article] [PubMed] 129. Dissemond J, Gotte P, Mors J, et al. Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. Melanoma Res. 2003;13:253–258. [PubMed] 130. Spaner DE. Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells. J Leukoc Biol. 2004;76:338–351. [PubMed] 131. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647–654. [PMC free article] [PubMed] 132. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet. 2002;360:295–305. [PubMed] 133. Mitchell PJ, Welton J, Staffurth J, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009;7:4. [PMC free article] [PubMed] 134. Riteau B, Faure F, Menier C, et al. Exosomes bearing HLAG are released by melanoma cells. Hum Immunol. 2003;64:1064–1072. [PubMed] 135. Valenti R, Huber V, Iero M, et al. Tumor-released micro-vesicles as vehicles of immunosuppression. Cancer Res. 2007;67:2912–2915. [PubMed] 136. Yu S, Liu C, Su K, et al. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. 2007;178:6867–6875. [PubMed] 137. Ichim TE, Zhong Z, Kaushal S, et al. Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med. 2008;6:37. [PMC free article] [PubMed] 138. Brown JA, Dorfman DM, Ma FR, et al. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–1266. [PubMed] 139. Alegre ML, Shiels H, Thompson CB, et al. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol. 1998;161:3347–3356. [PubMed] 140. Munn DH, Sharma MD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol. 2004;172:4100–4110. [PubMed] 141. Hurwitz AA, Foster BA, Kwon ED, et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 2000;60:2444–2448. [PubMed] 142. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A. 1999;96:15074–15079. [PubMed] 143. Van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190:355–366. [PMC free article] [PubMed] 144. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol. 2008;128:2596–2605. [PubMed] 145. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13(22 Pt 1):6681–6688. [PMC free article] [PubMed] 146. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100:8372–8377. [PubMed]
147. Fischkoff SA, Hersh E, Weber J, et al. Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma. Proc Am Soc Clin Oncology. 2005;23:16S. Abstr. 7525.
148. Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–1016. [PMC free article] [PubMed] 149. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005;23:6043–6053. [PMC free article] [PubMed]
150. Weber JS, Hersh E, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma. Journal of Clinical Oncology. 2007;25(18S (June 20 Supplement)):8523. 2007 ASCO Annual Meeting Proceedings Part I.
151. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol. 2005;23:8968–8977. [PubMed]
152. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675, 206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol. 2008;26:1011s.
153. Kirkwood JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010;16:1042–1048. [PubMed]
154. Hamid O, Urba WJ, Yellin M, et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Journal of Clinical Oncology. 2007;25(18S (June 20 Supplement)):8525. 2007 ASCO Annual Meeting Proceedings Part I.
155. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005;23:741–750. [PubMed] 156. Comin-Anduix B, Lee Y, Jalil J, et al. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008;6:22–36. [PMC free article] [PubMed] 157. Menard C, Ghiringhelli F, Roux S, et al. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res. 2008;14:5242–5249. [PubMed]
158. Richmond J, Gao F, Wood L, et al. Pharmacogenetic analysis of CTLA4 gene polymorphisms and response to tremelimumab in patients with advanced melanoma. Journal of Clinical Oncology. 2008 Presented at: 44th annual meeting of the American Society of Clinical Oncology. Abstract 14003.
159. Breunis WB, Tarazona-Santos E, Chen R, et al. Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother. 2008;31:586–590. [PMC free article] [PubMed] 160. Ohigashi Y, Sho M, Yamada Y, et al. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 2005;11:2947–2953. [PubMed] 161. Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99:12293–12297. [PubMed] 162. Blank C, Kuball J, Voelkl S, et al. Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119:317–327. [PubMed] 163. O'Sullivan B, Thomas R. CD40 and dendritic cell function. Crit Rev Immunol. 2003;23:83–107. [PubMed] 164. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780–787. [PubMed] 165. Hunter TB, Alsarraj M, Gladue RP, et al. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65:479–486. [PubMed] 166. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876–883. [PubMed]
167. Kruit WH, van Ojik H, Portielje J, et al. Phase I/II study with CpG 7909 as adjuvant to vaccination with MAGE-3 protein in patients with MAGE-3 positive tumors. Journal of Clinical Oncology. Proc Am Soc Clin Oncol. 2002;21 abstr 1854.
168. Wagner SN, Pashenkov M, Goess G, et al. TLR-9-targeted CpG immunostimulatory treatment of metastatic melanoma: a phase II trial with CpG 7909 (promune) Journal of Clinical Oncology. Proc Am Soc Clin Oncology. 2004;22:14S. Abstr. 7513.
169. Wagner S, Weber J, Redman B, et al. CPG 7909, a TLR9 Agonist Immunomodulator in Metastatic Melanoma: A Randomized Phase II Trial Comparing Two Doses and in Combination with DTIC. Journal of Clinical Oncology. 2005;23:16S. ASCO Annual Meeting Proceedings. Part I of II. 7526.
170. Pashenkov M, Goess G, Wagner C, et al. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006;24:5716–5724. [PubMed] 171. Hofmann MA, Kors C, Audring H, et al. Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma. J Immunother. 2008;31:520–527. [PubMed] 172. Lehner M, Morhart P, Stilper A, et al. Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother. 2007;30:312–322. [PubMed] 173. Birmachu W, Gleason RM, Bulbulian BJ, et al. Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists. BMC Immunol. 2007;8:26. [PMC free article] [PubMed] 174. Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441–1451. [PMC free article] [PubMed] 175. Ramakrishna V, Vasilakos JP, Tario JD, et al. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med. 2007;5:5. [PMC free article] [PubMed] 176. Li VW, Li WW, Talcott KE, et al. Imiquimod as an antiangiogenic agent. J Drugs Dermatol. 2005;4:708–717. [PubMed] 177. Shackleton M, Davis ID, Hopkins W, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 2004;4:9. [PubMed] 178. Steinmann A, Funk JO, Schuler G, et al. Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000;43:555–556. [PubMed] 179. Shistik G, Prakash AV, Fenske NA, et al. Treatment of locally metastatic melanoma: a novel approach. J Drugs Dermatol. 2007;6:830–832. [PubMed] 180. Suzuki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol. 2000;114:135–141. [PubMed] 181. Burns RP, Ferbel B, Tomai M, et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol. 2000;94:13–23. [PubMed] 182. Schon MP, Wienrich BG, Drewniok C, et al. Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod. J Invest Dermatol. 2004;122:1266–1276. [PubMed] 183. Baumgartner JM, Gonzalez R, Lewis KD, et al. Increased survival from stage IV melanoma associated with fewer regulatory T cells. J Surg Res. 2008 [PubMed] 184. Fehervari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest. 2004;114:1209–1217. [PMC free article] [PubMed] 185. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330–336. [PubMed] 186. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med. 2007;13:108–116. [PubMed] 187. Bopp T, Becker C, Klein M, et al. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med. 2007;204:1303–1310. [PMC free article] [PubMed] 188. Kim-Schulze S, Kim HS, Fan Q, et al. Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment. Mol Ther. 2009;17:380–388. [PubMed]
189. Davis ID, Brady B, Kefford R, et al. Activity of recombinant human interleukin-21 (rIL-21) in patients (pts) with stage IV malignant melanoma (MM) without prior treatment: clinical data from a phase IIa study. J Clin Oncol. 2008;26
190. Schmidt H, Selby P, Mouritzen U, et al. Subcutaneous (SC) dosing of recombinant human interleukin-21 (rIL-21) is safe and has clinical activity: results from a dose-escalation study in stage 4 melanoma (MM) or renal cell cancer (RCC) J Clin Oncol. 2008 May 20;26(suppl) abstr 3041.
191. Nair S, Boczkowski D, Fassnacht M, et al. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res. 2007;67:371–380. [PubMed] 192. Kong LY, Wei J, Sharma AK, et al. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2008 [PMC free article] [PubMed] 193. Kavanagh B, O'Brien S, Lee D, et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008;112:1175–1183. [PubMed] 194. Van der Vliet HJ, Koon HB, Yue SC, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13:2100–2108. [PubMed] 195. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–1177. [PubMed] 196. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 2006;107:628–636. [PubMed] 197. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409–2414. [PubMed] 198. Powell DJ, Attia P, Ghetie V, et al. Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother. 2008;31:189–198. [PMC free article] [PubMed] 199. Powell DJ, Felipe-Silva A, Merino MJ, et al. Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo. J Immunol. 2007;179:4919–4928. [PMC free article] [PubMed] 200. Scott AM, Lee FT, Hopkins W, et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol. 2001;19:3976–3987. [PubMed] 201. Scott AM, Liu Z, Murone C, et al. Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma. Cancer Immun. 2005;5:3. [PubMed] 202. Becker JC, Pancook JD, Gillies SD, et al. T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med. 1996;183:2361–2366. [PMC free article] [PubMed] 203. Choi BS, Sondel PM, Hank JA, et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother. 2006;55:761–774. [PubMed]
204. Cheng JD, Adams GP, Robinson MK, et al. Chapter 16: Pharmacology of Cancer Biotherapeutics: Section 4: Monoclonal Antibodies. In: De Vita VT Jr, Hellman S, Rosenberg SA, et al., editors. Biologic Therapy of Cancer Principles and Practice. 7th ed. JB Lippincot; Philadelphia: 2003. p. 576.
205. Brasoveanu LI, Altomonte M, Fonsatti E, et al. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest. 1996;74:33–42. [PubMed] 206. Parkinson DR. Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol. 1991;9:716–717. [PubMed] 207. Lipton A, Harvey HA, Balch CM, et al. Corynebacterium parvum versus bacille Calmette-Guerin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol. 1991;9:1151–1156. [PubMed] 208. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670–1677. [PubMed] 209. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20:1818–1825. [PubMed] 210. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006;354:709–718. [PubMed] 211. Eggermont AM. The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer. 2001;37:2147–2153. [PubMed] 212. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet. 2001;358:866–869. [PubMed] 213. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53–61. [PubMed] 214. Pectasides D, Dafni U, Bafaloukos D, et al. Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol. 2009;27:939–944. [PubMed] 215. Von Rohr A, Ghosh AK, Thatcher N, et al. Immunomodulation during prolonged treatment with combined interleukin-2 and interferon-alpha in patients with advanced malignancy. Br J Cancer. 1993;67:163–171. [PMC free article] [PubMed] 216. Hauschild A, Weichenthal M, Balda BR, et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21:2883–2888. [PubMed] 217. Stadler R, Luger T. Long term survival benefit after adjuvant treatment of high risk cutaneous melanoma with dacarbazine and low dose natural interferon alpha: a controlled, randomized, multicentre trial. Journal of Clinical Oncology. Proc Am Soc Clin Oncology. 2005 Abstr. 7516. [PubMed] 218. Bottomley A, Coens C, Suciu S, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol. 2009;27:2916–2923. [PubMed] 219. Eggermont AM, Bouwhuis MG, Kruit WH, et al. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991) Cancer Chemother Pharmacol. 2010;65:671–677. [PubMed] 220. Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006;24:3164–3171. [PubMed] 221. Buzaid AC, Colome M, Bedikian A, et al. Phase II study of neoadjuvant concurrent biochemotherapy in melanoma patients with local-regional metastases. Melanoma Res. 1998;8:549–556. [PubMed]
222. Mitchell MS, Abrams J, Kashani-Sabet M, et al. Interim analysis of a phase III stratified randomized trial of Melacine +low-dose Intron-A versus high-dose Intron-A for resected stage III melanoma. Journal of Clinical Oncology. Proc Am Soc Clin Oncology. 2003;22 Abstr. 2851.
223. Zimmerer JM, Lesinski GB, Ruppert AS, et al. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha. Clin Cancer Res. 2008;14:5900–5906. [PMC free article] [PubMed] 224. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol. 1998;25:623–635. [PubMed] 225. Morton DL, Hoon DS, Nizze JA, et al. Polyvalent melanoma vaccine improves survival of patients with metastatic melanoma. Ann N Y Acad Sci. 1993;690:120–134. [PubMed] 226. Lotem M, Peretz T, Drize O, et al. Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer. Br J Cancer. 2002;86:1534–1539. [PMC free article] [PubMed] 227. Bystryn JC. Clinical activity of a polyvalent melanoma antigen vaccine. Recent Results Cancer Res. 1995;139:337–348. [PubMed] 228. Sondak VK, Liu PY, Tuthill RJ, et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol. 2002;20:2058–2066. [PubMed]
229. Sondak VK, Sosman J, Unger JM, et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. Journal of Clinical Oncology. Proc Am Soc Clin Oncology. 2004;22:14S. Abstr. 7501.
230. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer. 1995;75(2 suppl):726–734. [PubMed] 231. Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg. 2002;236:438–448. discussion 448–449. [PubMed] 232. Hsueh EC, Essner R, Foshag LJ, et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol. 2002;20:4549–4554. [PubMed]
233. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. Journal of Clinical Oncology. Proc ASCO. 2007;25:18S. Abstract 8508.
234. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res. 2001;7:1882–1887. [PubMed] 235. Livingston PO, Natoli EJ, Calves MJ, et al. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A. 1987;84:2911–2915. [PubMed] 236. Livingston PO, Wong GY, Adluri S, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglio-side. J Clin Oncol. 1994;12:1036–1044. [PubMed] 237. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370–2380. [PubMed]
238. Eggermont A, Suciu S, Ruka W, et al. EORTC 18961: Postoperative adjuvant ganglioside GM2-KLH21 vaccination treatment versus observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results (abstract) J Clin Oncol. 2008;26:484s.
239. Slingluff CL, Petroni G, Bullock KA, et al. Immunological results of a phase II randomized trial of multipeptide vaccines for melanoma. Proc Am Soc Clin Oncology. 2004;22:14S. Abstr. 7503.
240. McCaffery M, Yao TJ, Williams L, et al. Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res. 1996;2:679–686. [PubMed] 241. Molenkamp BG, Sluijter BJ, Van Leeuwen PA, et al. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res. 2008;14:4532–4542. [PubMed] 242. Molenkamp BG, Van Leeuwen PA, Meijer S, et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res. 2007;13:2961–2969. [PubMed] 243. Spitler LE, Grossbard ML, Ernstoff MS, et al. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 2000;18:1614–1621. [PubMed]
244. Elias EG, Zapas JL, Beam SL, et al. Granulocyte-macro-phage colony stimulating factor (GM-CSF) & interleukin-2 (IL-2) combination as adjuvant therapy in cutaneous melanoma. Early results of a phase II clinical trial. Proc Am Soc Clin Oncology. 2004;22:14S. Abstr. 7559.
245. Butterfield LH, Disis ML, Fox BA, et al. A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers” J Transl Med. 2008;6:81. [PMC free article] [PubMed]